Results 191 to 200 of about 575,334 (316)

On the future of therapeutic vaccination in chronic hepatitis B

Future Science OA, 2019
Julio Cesar Aguilar Rubido
doaj   +1 more source

Exploring the Psychosocial Influences on Hepatitis B and Liver Cancer Disparities. [PDF]

J Racial Ethn Health Disparities
Block SJ, Zovich B, Borondy-Jenkins F, Chen T, Moraras K, Ansah B, Cohen C.   +6 more
europepmc   +1 more source

Expression of hepatitis B virus-specific markers in asymptomatic hepatitis B surface antigen carriers

, 1977
G. Arnold, J W Shih, Peter Kaplán, R H Purcell, John L. Gerin, K H Meyer Zum Bueschenfelde   +5 more
openalex   +1 more source

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea

British Journal of Clinical Pharmacology, EarlyView.
Aims Demographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
Natália Bordin Andriguetti, Daniel Thomas Barratt, Joseph Tucci, Paul Pumuye, Andrew Alexander Somogyi   +4 more
wiley   +1 more source

Hepatitis B virus genotype distribution and mutation patterns: Insights and clinical implications for hepatitis B virus positive patients. [PDF]

World J Exp Med
Ratnaparkhi MM, Vyawahare CR, Gandham NR.   +2 more
europepmc   +1 more source

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, Manjunath S. Shet, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

Accurate and Cost-Efficient Whole Genome Sequencing of Hepatitis B Virus Using Nanopore. [PDF]

J Med Virol
Stenbäck JB, Schmidt D, Noborg U, Gustafsson J, Norberg P, Andersson ME, Fu MX, Harvala H, Ringlander J.   +8 more
europepmc   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus. [PDF]

Vaccine
Vysotskaya V, Gassowski M, Kasper A, Gasich E, Kolomiets N, Dashkevich A, Wannemuehler K, Dubovik O, Mosina L.   +8 more
europepmc   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source